Skip to main content

Advertisement

SpringerLink
Log in

Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 03 July 2022

Abstract

Purpose

The aim of our study was to evaluate and compare the expression of different immunohistochemical markers in Bladder Carcinomas (BC) in patients with Neurogenic Bladder (NB) and Urinary Schistosomiasis (US) infection.

Materials and methods

We collected tissue samples from patients with Neurogenic Bladder and Bladder Carcinoma (NBC Group) and from patients with Urinary Schistosomiasis infection and Bladder Carcinoma (SBC Group). We compared to these two groups to control samples from resection from patients with Urinary Schistosomiasis without Bladder Carcinoma (US Group); we also investigate patients’ characteristics according to urothelial transitional cell carcinoma (TCC), and squamous cell carcinoma (SCC) histopathological differentiation. The expression of markers in all groups (CK7, CK14, CK20, FoxP3, GATA3, STAG2, CD3, CD8, Ki67, and P53) was analyzed using immunohistochemistry of tissue micro-array sections (TMA).

Results

Overall, 136 patients were included in the study (n = 72 in the NBC group, n = 33 in the SBC group, and n = 31 in the US group). In the TCC subgroup, the expression of CK7, CK14, CK20, and Ki67 was significantly higher compared to US controls (p 0.002; p < 0.001; p 0.036; p < 0.001). In the SCC subgroup, the expression of CK7, CK14, and CK20 was significantly higher compared to US controls (p 0.007; p < 0.001; p 0.005). Both in TCC and SCC subgroups, no difference in the expression of any tested markers was found comparing NBC and SBC groups. In US group, a significant higher expression of STAG2 was found compared to SCC subgroup (p 0.005).

Conclusion

Based on our results, the profile of immunohistochemical biomarkers’ expression in both NBC and SBC groups is similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BC:

Bladder carcinoma

NB:

Neurogenic bladder

US:

Urinary schistosomiasis

NBC:

Bladder carcinoma in neurogenic bladder patients

SBC:

Bladder carcinoma in patients with urinary schistosomiasis infection

TCC:

Transitional cell carcinoma

SCC:

Squamous cell carcinoma

PCC:

Papillary cell carcinoma

TURB:

Transurethral resection of the bladder

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin. https://doi.org/10.3322/caac.21654

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660

    Article  PubMed  Google Scholar 

  3. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci 8:1–12

    Google Scholar 

  4. Berry A, Iriart X, Fillaux J, Magnaval JF (2017) Schistosomose urogénitale et cancer. Bull Soc Pathol Exot. https://doi.org/10.1007/s13149-017-0547-4

    Article  PubMed  Google Scholar 

  5. Ismail S, Karsenty G, Chartier-Kastler E, Cussenot O, Compérat E, Rouprêt M, Phé V (2018) Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn 37:1386–1395

    Article  Google Scholar 

  6. Zaghloul MS, Gouda I (2012) Schistosomiasis and bladder cancer: Similarities and differences from urothelial cancer. Expert Rev Anticancer Ther 12:753–763

    Article  CAS  Google Scholar 

  7. Arslan B, Bozkurt IH, Yonguc T, Vardar E, Degirmenci T, Kozacioglu Z, Gunlusoy B, Minareci S (2015) Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: analysis of 125 cases. Urol Ann. https://doi.org/10.4103/0974-7796.150533

    Article  PubMed  PubMed Central  Google Scholar 

  8. Park JH, Moon KC (2018) Tumor, nodes, metastases (TNM) classification system for bladder cancer. Bladder Cancer. https://doi.org/10.1016/B978-0-12-809939-1.00012-6

    Article  Google Scholar 

  9. Phé V, Rouprêt M, Cussenot O, Chartier-Kastler E, Gamé X, Compérat E (2015) Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. BJU Int 115:28–32

    Article  Google Scholar 

  10. Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F (2009) Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. https://doi.org/10.1186/1756-9966-28-27

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hassan HE, Mohamed AAB, Bakhiet AO, Ahmed HG (2013) Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients. Infect Agents Cancer. https://doi.org/10.1186/1750-9378-8-9

    Article  Google Scholar 

  12. Badawy AA, El-Hindawi A, Hammam O, Moussa M, Helal NS, Kamel A (2017) Expression of epidermal growth factor receptor and transforming growth factor alpha in cancer bladder: Schistosomal and non-schistosomal. Curr Urol 9:192–201

    Article  Google Scholar 

  13. Gouveia MJ, Santos J, Brindley PJ, Rinaldi G, Lopes C, Santos LL, da Costa JMC, Vale N (2015) Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. Cancer Lett 359:226–232

    Article  CAS  Google Scholar 

  14. El-Aal AAA, Emran AM, Al-Antably AS, el Saftawy EA, Bayoumy IR, Hassan NS, Badawi M (2015) Immunohistochemical pattern of T lymphocytes population within bilharzial-associated bladder neoplasm microenvironment. Int J Immunopathol Pharmacol 28:209–217

    Article  Google Scholar 

  15. Bernardo C, Cunha MC, Santos JH, da Costa JMC, Brindley PJ, Lopes C, Amado F, Ferreira R, Vitorino R, Santos LL (2016) Insight into the molecular basis of schistosoma haematobium-induced bladder cancer through urine proteomics. Tumor Biology 37:11279–11287

    Article  CAS  Google Scholar 

  16. Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. https://doi.org/10.1016/j.ccr.2014.01.009

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ishida K, Hsieh MH (2018) Understanding urogenital schistosomiasis-related bladder cancer: an update. Front Med. https://doi.org/10.3389/fmed.2018.00223

    Article  Google Scholar 

  18. Koonrungsesomboon N, Wadagni AC, Mbanefo EC (2015) Molecular markers and Schistosoma-associated bladder carcinoma: a systematic review and meta-analysis. Cancer Epidemiol 39:487–496

    Article  Google Scholar 

  19. Youssef RF, Shariat SF, Kapur P et al (2011) Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Hum Pathol. https://doi.org/10.1016/j.humpath.2010.07.012

    Article  PubMed  Google Scholar 

  20. Solomon DA, Kim JS, Bondaruk J et al (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. https://doi.org/10.1038/ng.2800

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lelo A, Prip F, Harris BT et al (2018) STAG2 is a biomarker for prediction of recurrence and progression in papillary non–muscle-invasive bladder cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-3244

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zaghloul MS, Zaghloul TM, Bishr MK, Baumann BC (2020) Urinary schistosomiasis and the associated bladder cancer: update. J Egypt Natl Canc Inst. https://doi.org/10.1186/s43046-020-00055-z

    Article  PubMed  Google Scholar 

  23. Sui X, Lei L, Chen L, Xie T, Li X (2017) Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget. https://doi.org/10.18632/oncotarget.21565

    Article  PubMed  PubMed Central  Google Scholar 

  24. Schlager TA, Legallo R, Innes D, Hendley JO, Peters CA (2011) B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol. https://doi.org/10.1016/j.juro.2011.07.114

    Article  PubMed  Google Scholar 

  25. Sharma P, Shen Y, Wen S et al (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.0611618104

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One. https://doi.org/10.1371/journal.pone.0205746

    Article  PubMed  PubMed Central  Google Scholar 

  27. Krpina K, Babarović E, Jonjić N (2015) Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch. https://doi.org/10.1007/s00428-015-1808-6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank for the help in lab work Géraldine Cancel-Tassin. We would like to thank Dr. Anne Cremades, Dr. Céline Bazille, Pr Pierre Gosset, Dr. Laurent Daniel, Dr. Philippe Rouvier, Dr. Anne Durlach, Dr. Nathalie Rioux Leclercq, Dr. Sarah Pericart, Dr. Carla Fernandez, Dr. Aurélien Rock, Dr. Grégoire Léon, Dr. François-Régis Desfemmes, Dr. Benoît Peyronnet, Dr. Jérémy Fallot, Dr. Priscilla Léon, Dr. Emmanuel Rolland, Dr. Eric Huyghe, Dr. Xavier Gamé, Dr. Marie-Aimée Perrouin-Verbe, Dr. Jacques Wodey, Dr. Grégoire Capon, and Dr. Alain Ruffionfor for their participation in this project. We also thank the French Association of Urology (Association Française d’Urologie-AFU) and the French-speaking Neuro-Urology study group for supporting this work.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences and Translational Medicine, Sapienza Univeristà di Roma, Sant ’Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy

    Fabiana Cancrini

  2. Department of Urology and Kidney Transplantation, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France

    Floriane Michel

  3. Sorbonne University, GRC n°5, ONCOTYPE-URO, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    Fabiana Cancrini, Floriane Michel, Olivier Cussenot, Hussa Alshehhi, Eva Comperat & Véronique Phé

  4. Department of Pathology, Tenon Hospital, AP-HP. Sorbonne University, Paris, France

    Hussa Alshehhi & Eva Comperat

Authors
  1. Fabiana Cancrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Floriane Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Cussenot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hussa Alshehhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eva Comperat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Véronique Phé
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FC: research design, acquisition, analysis and interpretation of data; draft the paper, approved the submitted and final versions. FM: research design, acquisition of data; revised the paper critically; approved the submitted and final versions. OC: research design; revised the paper critically; approved the submitted and final versions. HA: pathological analysis of specimen; revised the paper critically; approved the submitted and final versions. EC: pathological analysis of specimen; revised the paper critically; approved the submitted and final versions. VP: research design, interpretation of data; revised the paper critically; approved the submitted and final versions.

Corresponding author

Correspondence to Fabiana Cancrini.

Ethics declarations

Conflict of interest

The authors have no competing interests.

Human participants

The research involved human tissue collected for diagnostic purposes and conserved in the Pathology Lab in Tenon Hospital, Sorbonne University, Paris France.

Informed consent

The collection and use of all bladder tissue samples was performed after the approval of the local ethics committee, informed consent, and in accordance with all relevant laws, regulations, and codes of practice in France.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cancrini, F., Michel, F., Cussenot, O. et al. Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?. World J Urol 40, 1949–1959 (2022). https://doi.org/10.1007/s00345-022-03941-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-022-03941-4

Keywords

Search

Navigation